Oliveri, Roberto S
Genmab (Denmark)
3 papers on CoChatORCID 0009-0008-8833-4465
Most cited papers
- Verified
Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study
Hutchings, M., Mous, R., Clausen, M. R., Johnson, P., Linton, K. M., Chamuleau, M. E. D., Lewis, D. J., Sureda Balari, A., Cunningham, D., Oliveri, R. S., et al. (2021) · The Lancet
Lymphoma Diagnosis and TreatmentChronic Lymphocytic Leukemia Research
Cited by 337
- Verified
Semimechanistic Physiologically‐Based Pharmacokinetic/Pharmacodynamic Model Informing Epcoritamab Dose Selection for Patients With B‐Cell Lymphomas
Li, T., Hiemstra, I. H., Chiu, C., Oliveri, R. S., Elliott, B., DeMarco, D., Salcedo, T., Egerod, F. L., Sasser, K., Ahmadi, T., et al. (2022) · Clinical Pharmacology & Therapeutics
Monoclonal and Polyclonal Antibodies ResearchLymphoma Diagnosis and Treatment
Cited by 34
- Verified
Novel Semi-Mechanistic Model Leveraging Preclinical and Clinical Data to Inform the Recommended Phase 2 Dose (RP2D) Selection for Epcoritamab (DuoBody CD3xCD20)
Li, T., Hiemstra, I. H., Chiu, C., Oliveri, R. S., DeMarco, D., Salcedo, T. W., Lihme Egerod, F., & Gupta, M. (2020) · Blood
Monoclonal and Polyclonal Antibodies ResearchStatistical Methods in Clinical Trials
Cited by 4
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free